Media stories about Crispr Therapeutics (NASDAQ:CRSP) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.3911457911834 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
Several equities analysts have weighed in on CRSP shares. SunTrust Banks raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Piper Jaffray Companies reissued a “buy” rating and set a $22.75 price target (down previously from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. BidaskClub raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Finally, Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and an average price target of $28.45.
Shares of Crispr Therapeutics (NASDAQ CRSP) opened at $48.93 on Wednesday. Crispr Therapeutics has a fifty-two week low of $13.50 and a fifty-two week high of $51.60. The stock has a market capitalization of $2,250.00 and a price-to-earnings ratio of -152.91.
In other Crispr Therapeutics news, major shareholder Aktiengesellschaft Bayer acquired 527,472 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were acquired at an average price of $22.75 per share, for a total transaction of $11,999,988.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kurt Von Emster sold 37,754 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $26.76, for a total value of $1,010,297.04. The disclosure for this sale can be found here. Insiders have sold 298,850 shares of company stock worth $7,545,365 in the last 90 days. Insiders own 39.98% of the company’s stock.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.